Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
Baxter
Harvard Business School
Medtronic

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Netupitant

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Netupitant: Patents, clinical trial progress, indications

Netupitant is an investigational drug.

There have been 11 clinical trials for Netupitant. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.

The most common disease conditions in clinical trials are Vomiting, Nausea, and Neoplasms. The leading clinical trial sponsors are Helsinn Healthcare SA, PSI CRO AG, and Parexel.

There are twenty-eight US patents protecting this investigational drug and three hundred and ninety-one international patents.

Recent Clinical Trials for Netupitant
TitleSponsorPhase
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly CisplatinHelsinn Healthcare SAPhase 2/Phase 3
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly CisplatinChristina RuhlmannPhase 2/Phase 3
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast CanceGeorge Clinical Pty LtdPhase 3

See all Netupitant clinical trials

Clinical Trial Summary for Netupitant

Top disease conditions for Netupitant
Top clinical trial sponsors for Netupitant

See all Netupitant clinical trials

US Patents for Netupitant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Netupitant   Start Trial Crystalline forms of fosnetupitant Helsinn Healthcare SA (Lugano/Pazzallo, CH)   Start Trial
Netupitant   Start Trial Brain, spinal, and nerve injury treatment EUSTRALIS PHARMACEUTICALS LIMITED (Melbourne, Victoria, AU)   Start Trial
Netupitant   Start Trial Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-to- lyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnet- upitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator Helsinn Healthcare SA (Lugano/Pazzallo, CH)   Start Trial
Netupitant   Start Trial Crystalline forms of an NK-1 antagonist Helsinn Healthcare SA (Pazzallo-Lugano, CH)   Start Trial
Netupitant   Start Trial Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system Chase Pharmaceuticals Corporation (Washington, DC)   Start Trial
Netupitant   Start Trial 4-phenyl-pyridine derivatives Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Netupitant

Drugname Country Document Number Estimated Expiration Related US Patent
Netupitant Australia 2016335060 2035-10-06   Start Trial
Netupitant Canada 2996466 2035-10-06   Start Trial
Netupitant China 108137626 2035-10-06   Start Trial
Netupitant European Patent Office 3359547 2035-10-06   Start Trial
Netupitant Japan 2018531249 2035-10-06   Start Trial
Netupitant South Korea 20180064453 2035-10-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Johnson and Johnson
Medtronic
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.